^
Association details:
| Biomarker: | AXL overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression
Published date:
04/18/2020
Excerpt:
CH5126766 and R428 suppressed the phosphorylation of ERK and AKT, respectively, and their combination synergistically inhibited the growth of both cell lines with enhancement of apoptosis accompanied by the Bim up‐regulation. KRAS‐mutated ovarian cancer with high expression of AXL.
DOI:
https://doi.org/10.1111/cas.14414
